CD151 and cardiac hypertrophy: The findings were further validated through the assessment of myocyte size (Fig 1E), demonstrating that shCD151 effectively mitigated cardiac hypertrophy induced by TAC, while CD151 overexpression exacerbated the development of cardiac hypertrophy.